BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10071302)

  • 1. RAS and leukemia: from basic mechanisms to gene-directed therapy.
    Beaupre DM; Kurzrock R
    J Clin Oncol; 1999 Mar; 17(3):1071-9. PubMed ID: 10071302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors and anti-Ras therapy.
    Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
    Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors versus Ras inhibitors.
    Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
    Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM; Adjei AA
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase as a target for anticancer drug design.
    Qian Y; Sebti SM; Hamilton AD
    Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
    O'Regan RM; Khuri FR
    Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
    Perrin D; Halazy S; Hill B
    Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.